Washington Trust’s Foghorn Therapeutics FHTX Stock Holding History

Washington Trust’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,500	Closed	-$5.47K	–	413
2025 Q1	$5.47K	Hold	1,500	–	–	﹤0.01%	650
2024 Q4	$7.08K	Hold	1,500	–	–	﹤0.01%	699
2024 Q3	$14K	Hold	1,500	–	–	﹤0.01%	638
2024 Q2	$8.63K	Hold	1,500	–	–	﹤0.01%	672
2024 Q1	$10.1K	Hold	1,500	–	–	﹤0.01%	664
2023 Q4	$9.68K	Hold	1,500	–	–	﹤0.01%	640
2023 Q3	$7.5K	Hold	1,500	–	–	﹤0.01%	651
2023 Q2	$10.6K	Hold	1,500	–	–	﹤0.01%	639
2023 Q1	$9.3K	Hold	1,500	–	–	﹤0.01%	663
2022 Q4	$9.57K	Hold	1,500	–	–	﹤0.01%	653
2022 Q3	$13K	Hold	1,500	–	–	﹤0.01%	612
2022 Q2	$20K	Hold	1,500	–	–	﹤0.01%	545
2022 Q1	$23K	Hold	1,500	–	–	﹤0.01%	549
2021 Q4	$34K	Buy	+1,500	New	+$21.6K	﹤0.01%	498

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Washington Trust's FHTX Position: Q2 2025 in Review

Washington Trust sold out of Foghorn Therapeutics (FHTX) in Q2 2025, closing a stake of 1,500 shares — an estimated $5.47K sold.

Washington Trust first reported a position in FHTX in Q4 2021 and held it in 14 quarters. The position peaked at $34K in Q4 2021. 81 funds tracked by Wall St. Rank hold FHTX as of Q2 2025.

Washington Trust reported no remaining Foghorn Therapeutics position as of Q2 2025 after selling out during the quarter.
Washington Trust sold 1,500 Foghorn Therapeutics shares in Q2 2025, an estimated $5.47K.
Washington Trust first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 14 quarters.
Washington Trust's Foghorn Therapeutics position peaked at $34K in Q4 2021.
81 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2025.

Based on Washington Trust's 13F filing for Q2 2025, filed 8 Aug 2025.